By Fineline Cube 
Merck & Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of 2026, with total worldwide sales of USD 16.6 billion, growing 4% year-over-year (ex-FX). The company is raising and narrowing its full-year 2026 sales outlook to a range of USD 66.3 billion to USD 67.3 billion, reflecting continued strength in oncology and successful recent launches.
Financial Performance Snapshot
| Metric | Q2 2026 | YoY Change (ex-FX) | Full-Year 2026 Guidance |
|---|---|---|---|
| Total Worldwide Sales | USD 16.6B | +4% | USD 66.3–67.3B (raised and narrowed) |
| Keytruda Franchise | USD 8.4B | +4% | Core growth driver |
| Keytruda QLEX | USD 463M | Not disclosed (new launch) | Subcutaneous formulation gaining traction |
| Winrevair | USD 588M | +75% | Pulmonary arterial hypertension blockbuster |
Oncology Portfolio Performance
Keytruda Franchise Expansion
- Total Keytruda Revenue: USD 8.4 billion (+4% YoY)
- Keytruda QLEX (subcutaneous): USD 463 million in initial uptake
- Formulation Innovation: Subcutaneous injection (pembrolizumab + berahyaluronidase alfa-pmph) offering patient convenience
- Market Leadership: Continued dominance in PD-1 inhibitor space despite competitive pressure
Pipeline Advancement Highlights
- Sacituzumab Tirumotecan (sac-TMT): Positive data from TroFuse-005 trial
- Indication: Advanced or recurrent endometrial cancer
- Technology: TROP2 antibody-drug conjugate (ADC)
- Partnership: Co-developed with Kelun-Biotech
- Strategic Value: Expands Merck’s ADC portfolio beyond existing assets
Cardiovascular & Rare Disease Launches
Winrevair (sotatercept)
- Q2 Sales: USD 588 million (+75% YoY)
- Indication: Pulmonary arterial hypertension (PAH)
- Growth Trajectory: Demonstrating blockbuster potential with rapid adoption
- Therapeutic Innovation: Novel approach to PAH treatment addressing unmet need
Lipfendra (enlicitide) Approval
- Regulatory Milestone: FDA approval received during Q2
- Innovation: First and only once-daily oral PCSK9 inhibitor
- Indication: LDL-C reduction in adults with hypercholesterolemia
- Market Potential: Oral administration offers significant advantage over injectable PCSK9 inhibitors
HIV Pipeline Breakthrough
Once-Weekly Oral HIV Regimen
- Combination: Islatravir + lenacapavir
- Development Stage: Positive Phase 3 results announced
- Partnership: Collaboration with Gilead Sciences
- Therapeutic Innovation: Potential first once-weekly oral HIV treatment regimen
- Market Impact: Could revolutionize HIV treatment paradigm with improved adherence
Strategic Business Dynamics
Portfolio Diversification Success
- Oncology Strength: Keytruda franchise maintaining growth despite patent concerns
- Rare Disease Expansion: Winrevair establishing strong foothold in PAH market
- Cardiovascular Innovation: Lipfendra approval creates new revenue stream in large cholesterol market
- Infectious Disease Leadership: HIV pipeline maintaining Merck’s historical strength
Commercial Excellence
- Launch Execution: Winrevair’s 75% growth demonstrates effective commercial strategy
- Formulation Innovation: Keytruda QLEX subcutaneous option addressing patient preference
- Global Reach: Worldwide sales growth reflecting international market penetration
Forward Guidance & Strategic Outlook
Revised Full-Year Expectations
- Sales Guidance: Raised and narrowed to USD 66.3–67.3 billion
- Confidence Signal: Reflects strong H1 performance and positive H2 catalysts
- Growth Sustainability: Diversified portfolio reducing dependency on any single product
Pipeline Catalysts
- Lipfendra Commercial Launch: Expected to contribute meaningfully in H2 2026
- Sac-TMT Regulatory Pathway: Positive endometrial cancer data supports NDA submission
- HIV Regimen Development: Phase 3 success enables regulatory submissions and commercial planning
- Keytruda Lifecycle Management: QLEX formulation extending franchise longevity
Market Positioning
- Innovation Focus: Multiple first-in-class and best-in-class assets across therapeutic areas
- Partnership Strategy: Strategic collaborations enhancing pipeline depth and commercial reach
- Financial Discipline: Strong cash flow supporting both shareholder returns and R&D investment
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, regulatory approvals, and pipeline development. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market access challenges, and clinical trial outcomes.-Fineline Info & Tech